Oncology & Cancer

ASCO: anticoagulant use predicts metastatic prostate CA survival

(HealthDay)—Anticoagulant use is associated with improved overall survival in men receiving docetaxel chemotherapy for treatment of metastatic castration-resistant prostate cancer (mCRPC), according to research presented ...

Oncology & Cancer

Cabazitaxel can offer an advantage in certain patients

Cabazitaxel (trade name: Jevtana) has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic ...

page 6 from 8